Sökning: id:"swepub:oai:DiVA.org:uu-149043" >
Dabigatran Versus W...
Dabigatran Versus Warfarin in Patients With Atrial Fibrillation An Analysis of Patients Undergoing Cardioversion
-
Nagarakanti, Rangadham (författare)
-
Ezekowitz, Michael D. (författare)
-
- Oldgren, Jonas (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala kliniska forskningscentrum (UCR)
-
visa fler...
-
Yang, Sean (författare)
-
Chernick, Michael (författare)
-
Aikens, Timothy H. (författare)
-
Flaker, Greg (författare)
-
Brugada, Josep (författare)
-
Kamensky, Gabriel (författare)
-
Parekh, Amit (författare)
-
Reilly, Paul A. (författare)
-
Yusuf, Salim (författare)
-
Connolly, Stuart J. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2011
- 2011
- Engelska.
-
Ingår i: Circulation. - 0009-7322 .- 1524-4539. ; 123:2, s. 131-136
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background-The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial compared dabigatran 110 mg BID (D110) and 150 mg BID (D150) with warfarin for stroke prevention in 18 113 patients with nonvalvular atrial fibrillation. Methods and Results-Cardioversion on randomized treatment was permitted. Precardioversion transesophageal echocardiography was encouraged, particularly in dabigatran-assigned patients. Data from before, during, and 30 days after cardioversion were analyzed. A total of 1983 cardioversions were performed in 1270 patients: 647, 672, and 664 in the D110, D150, and warfarin groups, respectively. For D110, D150, and warfarin, transesophageal echocardiography was performed before 25.5%, 24.1%, and 13.3% of cardioversions, of which 1.8%, 1.2%, and 1.1% were positive for left atrial thrombi. Continuous treatment with study drug for >= 3 weeks before cardioversion was lower in D110 (76.4%) and D150 (79.2%) compared with warfarin (85.5%; P<0.01 for both). Stroke and systemic embolism rates at 30 days were 0.8%, 0.3%, and 0.6% (D110 versus warfarin, P=0.71; D150 versus warfarin, P=0.40) and similar in patients with and without transesophageal echocardiography. Major bleeding rates were 1.7%, 0.6%, and 0.6% (D110 versus warfarin, P=0.06; D150 versus warfarin, P=0.99). Conclusions-This study is the largest cardioversion experience to date and the first to evaluate a novel anticoagulant in this setting. The frequencies of stroke and major bleeding within 30 days of cardioversion on the 2 doses of dabigatran were low and comparable to those on warfarin with or without transesophageal echocardiography guidance. Dabigatran is a reasonable alternative to warfarin in patients requiring cardioversion.
Nyckelord
- anticoagulants
- arrhythmia
- atrial fibrillation
- cardioversion
- stroke prevention
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Nagarakanti, Ran ...
-
Ezekowitz, Micha ...
-
Oldgren, Jonas
-
Yang, Sean
-
Chernick, Michae ...
-
Aikens, Timothy ...
-
visa fler...
-
Flaker, Greg
-
Brugada, Josep
-
Kamensky, Gabrie ...
-
Parekh, Amit
-
Reilly, Paul A.
-
Yusuf, Salim
-
Connolly, Stuart ...
-
visa färre...
- Artiklar i publikationen
-
Circulation
- Av lärosätet
-
Uppsala universitet